pp-222 Tablets

Indication: Advanced/metastatic non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations Clinical stage: Phase 2 cohort enrolling Modality: Small molecule (mutant-selective irreversible HER2 exon20 TKI — NCE) Mechanism / Target: Selective irreversible covalent inhibitor of HER2 kinase harbouring exon 20 insertion mutations; superior selectivity for HER2 exon20 mutant over wild-type HER2 and EGFR; prevents ABCG2 (breast cancer resistance protein) transporter-mediated drug efflux — mechanism overcoming a primary resistance pathway; blocks tumour cell proliferation driven by constitutively active HER2 exon20 insertions Route / form: Oral tablet or capsule Differentiation: Mutant-selective HER2 exon20 TKI with anti-ABCG2 efflux resistance advantage;